No influence of pantoprazole on the pharmacokinetics of phenytoin

Int J Clin Pharmacol Ther. 1996 May;34(1 Suppl):S72-5.

Abstract

Twenty-three healthy, male volunteers completed this doubleblind, randomized, placebo controlled, 2-period crossover study to assess the influence of multiple doses of pantoprazole on single-dose phenytoin pharmacokinetics. During each treatment period, the volunteers received either one 40 mg pantoprazole tablet or placebo for 7 days. In addition, a single-dose of 300 mg (3 x 100 mg capsules) phenytoin sodium was administered on day 4 of each treatment period. A 14-day wash-out period was allowed between phenytoin administrations. The results indicate that pantoprazole neither affects the rate nor the extent of absorption, nor the elimination of phenytoin.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Adolescent
  • Adult
  • Anticonvulsants / adverse effects
  • Anticonvulsants / pharmacokinetics*
  • Area Under Curve
  • Benzimidazoles / administration & dosage
  • Benzimidazoles / adverse effects
  • Benzimidazoles / pharmacology*
  • Cross-Over Studies
  • Double-Blind Method
  • Drug Interactions
  • Enzyme Inhibitors / administration & dosage
  • Enzyme Inhibitors / adverse effects
  • Enzyme Inhibitors / pharmacology*
  • Half-Life
  • Humans
  • Male
  • Omeprazole / analogs & derivatives
  • Pantoprazole
  • Phenytoin / adverse effects
  • Phenytoin / pharmacokinetics*
  • Proton Pump Inhibitors*
  • Sulfoxides / administration & dosage
  • Sulfoxides / adverse effects
  • Sulfoxides / pharmacology*

Substances

  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Anticonvulsants
  • Benzimidazoles
  • Enzyme Inhibitors
  • Proton Pump Inhibitors
  • Sulfoxides
  • Phenytoin
  • Pantoprazole
  • Omeprazole